Late Relapse of Acute Myelogenous Leukemia Followed by Epstein-Barr Virus—Associated Lymphoproliferative Disease 11 Years After Allogeneic Bone Marrow Transplantation

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) following myeloablative conditioning represents the treatment of choice for patients with chemotherapy-resistant leukemia. We describe a 49-year-old man with advanced, refractory acute myelogenous leukemia (AML) that was treated successfully by allogeneic bone marrow transplantation from a sibling donor with HLA mismatched at 1 locus. However, the patient developed a quiescent form of chronic graft-versus-host disease (GVHD) 7 years after transplantation, requiring long-term immunosuppressive therapy. AML relapse was documented 11 years after transplantation. Subsequently, Epstein-Barr virus (EBV)-associated posttransplantation lymphoprolif-erative disorder (PTLD) was also diagnosed. Immune reconstitution after allo-HSCT might have been impaired by the persistent chronic GVHD and the prolonged administration of immunosuppressive agents. As a result, immune surveillance against remaining quiescent leukemic cells as well as viral infection may have been defective, leading to the relapse of leukemia and EBV-associated PTLD.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Estey EH. Treatment of relapsed and refractory acute myeloge- nous leukemia. Leukemia. 2000;14:476–479.

    Article  CAS  PubMed  Google Scholar 

  2. 2.

    Stone RM, O’Donnell MR, Sekeres MA. Acute myeloid leukemia. Hematology (Am Soc Hematol Educ Program). 2004:98-117.

  3. 3.

    Song KW, Lipton J. Is it appropriate to offer allogeneic hemato- poietic stem cell transplantation to patients with primary refractory acute myeloid leukemia? Bone Marrow Transplant. 2005;36:183–191.

    Article  CAS  PubMed  Google Scholar 

  4. 4.

    Michallet M, Thomas X,Vernant JP, et al. Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Societe Française de Gréffé de Moelle (SFGM). Bone Marrow Transplant. 2000;26:1157–1163.

    Article  CAS  PubMed  Google Scholar 

  5. 5.

    Gale RP, Horowitz MM, Rees JK, et al. Chemotherapy versus transplants for acute myelogenous leukemia in second remission. Leukemia. 1996;10:13–19.

    CAS  PubMed  Google Scholar 

  6. 6.

    Lin J, Markowitz GS, Nicolaides M, et al. Membranous glomeru- lopathy associated with graft-versus-host disease following allo- geneic stem cell transplantation: report of 2 cases and review of the literature. Am J Nephrol. 2001;21:351–356.

    Article  CAS  PubMed  Google Scholar 

  7. 7.

    Rossi L, Cardarelli F, Vampa ML, Buzio C, Olivetti G. Membranous glomerulonephritis after haematopoietic cell transplantation for multiple myeloma. Nephron. 2001;88:260–263.

    Article  CAS  PubMed  Google Scholar 

  8. 8.

    Yamada K, Furusawa S, Saito K, et al. Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia: a pilot study. Leukemia. 1995;9:10–14.

    CAS  PubMed  Google Scholar 

  9. 9.

    Beatty PG, Clift RA, Mickelson EM, et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med. 1985;313:765–771.

    Article  CAS  PubMed  Google Scholar 

  10. 10.

    Anasetti C, Amos D, Beatty PG, et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med. 1989;320:197–204.

    Article  CAS  PubMed  Google Scholar 

  11. 11.

    Anasetti C, Beatty PG, Storb R, et al. Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Hum Immunol. 1990;29:79–91.

    Article  CAS  PubMed  Google Scholar 

  12. 12.

    Kanda Y, Chiba S, Hirai H, et al. Allogeneic hematopoietic stem cell transplantation from family members other than HLA-identi- cal siblings over the last decade (1991-2000). Blood. 2003;102: 1541–1547.

    Article  CAS  PubMed  Google Scholar 

  13. 13.

    Bertz H, Kunzman R, Bunjes D, Finke J. Successful adoptive immunotherapy for relapse of AML 9 years after T-cell-depleted BMT. Br J Haematol. 1998;103:563–564.

    Article  CAS  PubMed  Google Scholar 

  14. 14.

    Yong AS, Goldman JM. Relapse of chronic myeloid leukaemia 14 years after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1999;23:827–828.

    Article  CAS  PubMed  Google Scholar 

  15. 15.

    Shapiro RS, McClain K, Frizzera G, et al. Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood. 1988;71:1234–1243.

    CAS  PubMed  Google Scholar 

  16. 16.

    Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood. 1999;94:2208–2216.

    CAS  PubMed  Google Scholar 

  17. 17.

    Meijer E, Dekker AW, Weersink AJ, Rozenberg-Arska M, Verdonck LF. Prevention and treatment of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of bone marrow and solid organ transplants. Br J Haematol. 2002; 119:596–607.

    Article  CAS  PubMed  Google Scholar 

  18. 18.

    Bollard CM, Savoldo B, Rooney CM, Heslop HE. Adoptive T-cell therapy for EBV-associated post-transplant lymphoproliferative disease. Acta Haematol. 2003;110:139–148.

    Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding authors

Correspondence to Yoshikane Kikushige or Ken Takase or Toshihiro Miyamoto or Akihiko Numata or Kenjiro Kamesaki or Takahiro Fukuda or Koji Nagafuji or Hisashi Gondo or Mine Harada.

About this article

Cite this article

Kikushige, Y., Takase, K., Miyamoto, T. et al. Late Relapse of Acute Myelogenous Leukemia Followed by Epstein-Barr Virus—Associated Lymphoproliferative Disease 11 Years After Allogeneic Bone Marrow Transplantation. Int J Hematol 84, 441–444 (2006). https://doi.org/10.1532/IJH97.06113

Download citation

Key words

  • AML
  • Relapse
  • EBV-PTLD
  • BMT
  • GVHD